Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Calithera Biosciences & Incyte (INCY) announce global collaboration to develop & commercialize CB-1158; Calithera to receive a $45 mln up-front payment and an $8 mln equity investment from INCY through a share purchase priced at $4.65/share (4.60)<p>Arginase is an enzyme produced by immunosuppressive myeloid cells, including myeloid-derived suppressor cells and neutrophils, which prevents T-cell and natural killer cell activation in tumors.</p><ul><li>Incyte (<strong>INCY</strong>) gains worldwide rights to CB-1158 for hematology and oncology indications.</li><li>Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158.</li><li>Incyte will make an equity investment in Calithera of $8 million through the purchase of shares at a price of $4.65 per share.</li><li><strong>Calithera conference call scheduled today at 8:30 a.m. ET, 5:30 a.m. PT.</strong></li><li>The agreement also provides that Calithera may choose to opt out of its co-funding obligations. In this scenario, Calithera would no longer be eligible to receive future U.S. profits and losses but would be eligible to receive up to $750 million in potential development, regulatory and commercialization milestones from Incyte and, if the product is approved and commercialized, also be eligible to receive reimbursement based on previous development expenditures incurred by Calithera and tiered royalty payments on future global sales of CB-1158, with rates ranging from low-to-mid double-digits.</li><li>The transaction is expected to close in the first quarter of 2017</li></ul></td> </tr></table>"